The Adult Antiretroviral Treatment and Resistance Study (Tshepo)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00197613 |
Recruitment Status
:
Completed
First Posted
: September 20, 2005
Last Update Posted
: September 17, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
AIDS HIV Infection | Drug: (A) zidovudine, lamivudine and nevirapine Drug: (B) zidovudine, lamivudine and efavirenz Drug: (C) zidovudine, didanosine, and nevirapine Drug: (D) zidovudine, didanosine, and efavirenz Drug: (E) stavudine, lamivudine, and nevirapine Drug: (F) stavudine, lamivudine and efavirenz Procedure: Adherence Strategy Standard of Care (SOC) Procedure: Adherence Strategy Community-Based DOT | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 650 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Official Title: | The Adult Antiretroviral Treatment and Resistance Study (Tshepo) |
Study Start Date : | December 2002 |
Actual Study Completion Date : | December 2007 |

- Time to Virological failure, time to grade 3 or higher toxicity.
- Time to drug resistance, rates of point mutations at virological failure, adherence to study medication.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00197613
Botswana | |
Princess Marina Hospital | |
Gaborone, Botswana |
Principal Investigator: | Richard Marlink, MD | Harvard School of Public Health AIDS Initiative |
Responsible Party: | Richard Marlink, Professor of the Practice of Public Health, Harvard School of Public Health |
ClinicalTrials.gov Identifier: | NCT00197613 History of Changes |
Other Study ID Numbers: |
HSC #0110THEA |
First Posted: | September 20, 2005 Key Record Dates |
Last Update Posted: | September 17, 2012 |
Last Verified: | September 2012 |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Lamivudine Zidovudine Efavirenz Nevirapine Stavudine Didanosine |
Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Anti-HIV Agents Antimetabolites Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 CYP2C19 Inhibitors Cytochrome P-450 CYP2B6 Inducers Cytochrome P-450 Enzyme Inducers Cytochrome P-450 CYP3A Inducers |